Payers Come To Terms With Long-Term Coverage Of New CLL Drugs
WellPoint’s new oncology treatment pathway for CLL, released in September, will use higher payments to doctors to steer them to drugs it feels offer the best outcomes and value.
You may also be interested in...
GlaxoSmithKline exec Klaus Edvardsen says the new label should give drug a boost, as previous indication was very restrictive. Approved in 2009, Arzerra had just £75 million in 2013 worldwide sales.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.